SGLT2 Inhibitors and Ketoacidosis: Cause for Concern?

Metab Syndr Relat Disord. 2016 Feb;14(1):1-2. doi: 10.1089/met.2015.29002.aba. Epub 2015 Nov 10.

Authors

Nicola Abate¹, Manisha Chandalia²

Affiliations

¹ 1 Division of Endocrinology, University of Texas Medical Branch , Galveston, Texas.
² 2 Endocrine Clinics, Bayarea Metabolic Health , Houston, Texas.

PMID: 26554527
DOI: 10.1089/met.2015.29002.aba

No abstract available

MeSH terms

Biomarkers / blood
Blood Glucose / drug effects*
Blood Glucose / metabolism
Diabetes Mellitus, Type 2 / blood
Diabetes Mellitus, Type 2 / diagnosis
Diabetes Mellitus, Type 2 / drug therapy*
Diabetic Ketoacidosis / blood
Diabetic Ketoacidosis / chemically induced*
Diabetic Ketoacidosis / diagnosis
Evidence-Based Medicine
Humans
Hypoglycemic Agents / adverse effects*
Risk Assessment
Risk Factors
Sodium-Glucose Transporter 2 / metabolism
Sodium-Glucose Transporter 2 Inhibitors*

Substances

Biomarkers
Blood Glucose
Hypoglycemic Agents
SLC5A2 protein, human
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors